



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 11245/46211	<b>SERIAL NO.</b> 10/091,300
	<b>APPLICANT</b> ROCKWELL, et al.	
	<b>FILING DATE</b> March 4, 2002	<b>GROUP</b> 1648

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
DB	6,342,219	January 29, 2002	Thorpe et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
DB	Johnson D.L. et al., Dual inhibitors of the BFGF and VEGF receptor tyrosine kinases effectively inhibit angiogenesis. Proceedings of the American Associate for Cancer Research March 2000. Vol 41, Page 567. Abstract 3614
	Hooper H.A. et al., Vascular endothelial growth factor receptor (VEGFR-2) antibody therapy combined with conventional chemotherapy inhibits growth of established tumors in mice. Proceedings of the American associate for Cancer Research. March 2000 Vol. 41 page 567. Abstract 3613
V	Mordenti J. et al., Efficacy and Concentration-response to murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicologic Pathology 1999. Vol. 27, No. 1 pp. 14-21
DB	Hirota N. et al. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gefonin and monoclonal anti-epidermal growth factor receptor antibody. Cancer Research 1989, Vol. 49

<b>EXAMINER</b> <i>Paul B. B. B.</i>	<b>DATE CONSIDERED</b> 3/23/05
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	